What is Omeros?
Omeros Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious diseases. The company operates at the intersection of novel biological pathway research and advanced pharmacology, focusing on receptors and enzymes that remain largely untapped by conventional medicine. With a diversified pipeline, Omeros targets therapeutic areas where current standards of care are insufficient, positioning itself as a high-value innovator in the global life sciences market. Its operational strategy emphasizes proprietary intellectual property, which serves as the cornerstone for its long-term growth and market differentiation.
How much funding has Omeros raised?
Omeros has raised a total of $1.1B across 22 funding rounds:
Stock Offering
$84M
Multiple Rounds
$215M
Stock Offering
$63.6M
Debt
$210M
Stock Offering
$57.5M
Debt
$92.1M
Other Financing Round
$4M
Stock Issuance/Offering (2015): $84M, investors not publicly disclosed
Debt (2016): $50M backed by Oxford Finance and East West Bank
Stock Issuance/Offering (2016): $40M with participation from Cantor Fitzgerald & Co.
Debt (2016): $125M led by CRG LP
Stock Issuance/Offering (2017): $63.6M, investors not publicly disclosed
Debt (2018): $210M, investors not publicly disclosed
Stock Issuance/Offering (2019): $57.5M, investors not publicly disclosed
Debt (2024): $92.1M with participation from Athyrium Capital Management and Highbridge Capital Management
Other Financing Round (2025): $4M led by National Institute on Drug Abuse
Key Investors in Omeros
ARCH Ventures
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize university-led innovations.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal think tank to support clinical development.
Athyrium Capital Management
A prominent investment management platform specializing in structured investments, royalties, and credit within the global healthcare sector to support long-term growth objectives.
What's next for Omeros?
Looking ahead, the strategic deployment of the $4M will likely focus on accelerating clinical trial milestones and expanding the company's research infrastructure. As Omeros continues to refine its drug candidates, the focus will shift toward optimizing manufacturing processes and preparing for potential regulatory submissions. The company's ability to attract diverse institutional backing, including specialized healthcare investment firms and government research entities, provides a stable foundation for sustained growth. Investors will be closely monitoring the progression of the company's lead assets through late-stage clinical evaluations, which remain the primary catalysts for future value creation and market expansion.
See full Omeros company page
